Invention Grant
- Patent Title: Anti-PCSK9 antibodies
-
Application No.: US16334767Application Date: 2017-09-12
-
Publication No.: US11111313B2Publication Date: 2021-09-07
- Inventor: Jieying Liu , Jing Li
- Applicant: WuXi Biologies Ireland Limited
- Applicant Address: IE Dublin
- Assignee: WuXi Biologies Ireland Limited
- Current Assignee: WuXi Biologies Ireland Limited
- Current Assignee Address: IE Dublin
- Agency: Jun He Law Offices P.C.
- Agent James J. Zhu
- Priority: WOPCT/CN2016/099491 20160920
- International Application: PCT/CN2017/101357 WO 20170912
- International Announcement: WO2018/054241 WO 20180329
- Main IPC: C07K16/40
- IPC: C07K16/40 ; A61K39/395 ; C12N9/64 ; A61P3/06 ; A61P3/00 ; A61P37/04 ; A61P9/00 ; A61K39/00 ; A61P31/00
Abstract:
The present disclosure provides monoclonal antibodies against Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), which can block the binding of PCSK9 to low-density lipoprotein (LDL) receptor, and therefore lower the level low-density lipoprotein cholesterol (LDL-C). The antibodies of disclosure provide very potent agents for the treatment of multiple Cardiovascular diseases (CVDs).
Public/Granted literature
- US20190233542A1 Novel Anti-PCSK9 Antibodies Public/Granted day:2019-08-01
Information query
